首页 > 最新文献

Journal of Clinical Pathology最新文献

英文 中文
Deep learning predicts microsatellite instability status in colorectal carcinoma in an ethnically heterogeneous population in South Africa. 深度学习预测南非种族异质性人群结直肠癌的微卫星不稳定状态。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-12-15 DOI: 10.1136/jcp-2025-210053
Alessandro Pietro Aldera, Didem Cifci, Gregory Patrick Veldhuizen, Wan-Jung Tsai, Komala Pillay, Adam Boutall, Hermann Brenner, Michael Hoffmeister, Jakob Nikolas Kather, Raj Ramesar

Background: Deep learning (DL) models are effective pre-screening tools for detecting mismatch repair deficiency (dMMR) in colorectal carcinoma (CRC). These models have been trained and validated on large cohorts from the Northern Hemisphere, without representation of African samples. We sought to determine the performance of a DL model in an ethnically heterogeneous cohort of patients from South Africa.

Methods: Our cohort comprised 197 CRC resection specimens, with scanned whole slide images tessellated and inputted into a transformer-based DL model trained on large international cohorts. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC), sensitivity and specificity. The maximal Youden's J index was calculated to determine the optimal cut-off threshold for the model prediction score.

Results: Our model yielded an AUROC of 0.91 (±0.05). Using a prediction score threshold of 0.620 produced an overall sensitivity of 85.7% (95% CI 73.3% to 92.9%) and a specificity of 82.4% (95% CI 75.5% to 87.7%). The false negative cases were predominantly left-sided (71.4%) and did not show the typical dMMR/microsatellite instability-high histological phenotype. Sensitivity was lower (50%-75%) in cases showing isolated PMS2 or MSH6 loss of staining. Calibrating the classification threshold to 0.470, the sensitivity was optimised to 95.6% (95% CI 86.3% to 98.9%) with a specificity of 69.6% (95% CI 61.8% to 76.4%). This would have resulted in excluding 103 cases (52.3%) from downstream immunohistochemical (IHC) or molecular testing.

Conclusions: Following appropriate region-specific calibration, we have shown that this model could be employed to accurately prescreen for dMMR in CRC, thereby reducing the burden of downstream IHC and molecular testing in a resource-limited setting.

背景:深度学习(DL)模型是检测结直肠癌(CRC)错配修复缺陷(dMMR)的有效预筛选工具。这些模型已经在北半球的大型队列中进行了训练和验证,但没有代表非洲样本。我们试图确定DL模型在南非异种种族患者队列中的表现。方法:我们的队列包括197例CRC切除标本,扫描的整个切片图像被细分,并输入到基于变压器的DL模型中,该模型是在大型国际队列中训练的。采用受试者工作特征曲线下面积(AUROC)、敏感性和特异性评价模型的性能。计算最大约登J指数,确定模型预测分数的最优截止阈值。结果:模型的AUROC为0.91(±0.05)。使用0.620的预测评分阈值,总敏感性为85.7% (95% CI 73.3%至92.9%),特异性为82.4% (95% CI 75.5%至87.7%)。假阴性病例以左侧为主(71.4%),未表现出典型的dMMR/微卫星不稳定-高组织学表型。在分离的PMS2或MSH6染色丢失的病例中,敏感性较低(50%-75%)。将分类阈值校准为0.470,灵敏度优化为95.6% (95% CI 86.3%至98.9%),特异性为69.6% (95% CI 61.8%至76.4%)。这将导致103例(52.3%)患者从下游免疫组化(IHC)或分子检测中被排除。结论:经过适当的区域特异性校准,我们已经证明该模型可以用于准确地预筛选CRC中的dMMR,从而在资源有限的情况下减轻下游IHC和分子检测的负担。
{"title":"Deep learning predicts microsatellite instability status in colorectal carcinoma in an ethnically heterogeneous population in South Africa.","authors":"Alessandro Pietro Aldera, Didem Cifci, Gregory Patrick Veldhuizen, Wan-Jung Tsai, Komala Pillay, Adam Boutall, Hermann Brenner, Michael Hoffmeister, Jakob Nikolas Kather, Raj Ramesar","doi":"10.1136/jcp-2025-210053","DOIUrl":"10.1136/jcp-2025-210053","url":null,"abstract":"<p><strong>Background: </strong>Deep learning (DL) models are effective pre-screening tools for detecting mismatch repair deficiency (dMMR) in colorectal carcinoma (CRC). These models have been trained and validated on large cohorts from the Northern Hemisphere, without representation of African samples. We sought to determine the performance of a DL model in an ethnically heterogeneous cohort of patients from South Africa.</p><p><strong>Methods: </strong>Our cohort comprised 197 CRC resection specimens, with scanned whole slide images tessellated and inputted into a transformer-based DL model trained on large international cohorts. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC), sensitivity and specificity. The maximal Youden's J index was calculated to determine the optimal cut-off threshold for the model prediction score.</p><p><strong>Results: </strong>Our model yielded an AUROC of 0.91 (±0.05). Using a prediction score threshold of 0.620 produced an overall sensitivity of 85.7% (95% CI 73.3% to 92.9%) and a specificity of 82.4% (95% CI 75.5% to 87.7%). The false negative cases were predominantly left-sided (71.4%) and did not show the typical dMMR/microsatellite instability-high histological phenotype. Sensitivity was lower (50%-75%) in cases showing isolated PMS2 or MSH6 loss of staining. Calibrating the classification threshold to 0.470, the sensitivity was optimised to 95.6% (95% CI 86.3% to 98.9%) with a specificity of 69.6% (95% CI 61.8% to 76.4%). This would have resulted in excluding 103 cases (52.3%) from downstream immunohistochemical (IHC) or molecular testing.</p><p><strong>Conclusions: </strong>Following appropriate region-specific calibration, we have shown that this model could be employed to accurately prescreen for dMMR in CRC, thereby reducing the burden of downstream IHC and molecular testing in a resource-limited setting.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"50-56"},"PeriodicalIF":2.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results. 肺癌中HER2表达模式和基因组相关因素,重点关注影响免疫组织化学染色结果的分析前变量。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-12-15 DOI: 10.1136/jcp-2025-210095
Cristiana M Pineda, Lauren O'Loughlin, Heather L Benjamin, Deepa Rangachari, Hollis Viray, Page C Widick, Zoe Guan, Jason A Beattie, Kai E Swenson, Mihir S Parikh, Adnan Majid, Daniel B Costa, Paul A VanderLaan

Aims: Fam-trastuzumab deruxtecan-nxki (T-DXd) was recently approved for advanced stage or metastatic solid tumours with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) 3+ staining. Data on HER2 IHC testing and knowledge of genomic correlates in lung cancer are scarce. This study analyses genomic characteristics of HER2-expressing tumours and addresses issues with preanalytical variables for lung cancer specimens.

Methods: HER2 IHC staining was performed on selected archival cytology and surgical pathology lung cancer specimens for patients eligible for T-DXd therapy. Patient and tumour characteristics and next-generation sequencing (NGS) data were correlated with HER2 IHC results.

Results: 166 patients with thoracic tumour samples had HER2 expression assessed: 46% were IHC 0, 28% IHC 1+, 13% IHC 2+ and 13% IHC 3+. HER2 IHC scores were overall lower for cytology cell blocks as compared with surgical pathology specimens; 79% of cases with paired specimens had a decrease in their HER2 IHC score from their surgical specimen to their paired cytology specimen. Of specimens with HER2 IHC 3+ and NGS available, only 14% (3/21) had concomitant ERBB2 alterations. Among all specimens, ERBB2 point mutations were noted in 4% (4/110) and ERBB2 amplification in 3% (3/110). The majority of HER2 3+ cases with paired NGS (17/21, 81%) had non-ERBB2 genomic alterations, including: KRAS, TP53, and STK11 mutations.

Conclusions: HER2 IHC 3+ is seen in a small but clinically significant proportion of samples and is associated with a variety of co-occurring non-ERBB2 genomic alterations. Preanalytical variables including specimen fixation can significantly impact the assessment of HER2 expression via immunohistochemistry.

目的:Fam-trastuzumab deruxtecan-nxki(T-DXd)最近被批准用于人表皮生长因子受体 2(HER2)免疫组化(IHC)3+染色的晚期或转移性实体瘤。有关 HER2 IHC 检测的数据以及肺癌基因组相关知识尚不多见。本研究分析了HER2表达肿瘤的基因组特征,并探讨了肺癌标本分析前变量的问题。方法:对符合T-DXd治疗条件的患者的部分存档细胞学和手术病理学肺癌标本进行HER2 IHC染色。患者和肿瘤特征以及新一代测序(NGS)数据与 HER2 IHC 结果相关联:结果:166 名患者的胸部肿瘤样本接受了 HER2 表达评估:46%为IHC 0,28%为IHC 1+,13%为IHC 2+,13%为IHC 3+。与手术病理标本相比,细胞学细胞块的 HER2 IHC 得分总体较低;在配对标本中,79% 的病例从手术标本到配对细胞学标本的 HER2 IHC 得分都有所下降。在 HER2 IHC 3+ 且有 NGS 可查的标本中,只有 14%(3/21)的标本伴有 ERBB2 改变。在所有标本中,ERBB2 点突变占 4%(4/110),ERBB2 扩增占 3%(3/110)。大多数有配对 NGS 的 HER2 3+ 病例(17/21,81%)有非 ERBB2 基因组改变,包括结论:结论:HER2 IHC 3+ 可见于小部分样本中,但临床意义重大,且与多种并发的非 ERBB2 基因组改变相关。包括标本固定在内的分析前变量会显著影响免疫组化对HER2表达的评估。
{"title":"Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results.","authors":"Cristiana M Pineda, Lauren O'Loughlin, Heather L Benjamin, Deepa Rangachari, Hollis Viray, Page C Widick, Zoe Guan, Jason A Beattie, Kai E Swenson, Mihir S Parikh, Adnan Majid, Daniel B Costa, Paul A VanderLaan","doi":"10.1136/jcp-2025-210095","DOIUrl":"10.1136/jcp-2025-210095","url":null,"abstract":"<p><strong>Aims: </strong>Fam-trastuzumab deruxtecan-nxki (T-DXd) was recently approved for advanced stage or metastatic solid tumours with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) 3+ staining. Data on HER2 IHC testing and knowledge of genomic correlates in lung cancer are scarce. This study analyses genomic characteristics of HER2-expressing tumours and addresses issues with preanalytical variables for lung cancer specimens.</p><p><strong>Methods: </strong>HER2 IHC staining was performed on selected archival cytology and surgical pathology lung cancer specimens for patients eligible for T-DXd therapy. Patient and tumour characteristics and next-generation sequencing (NGS) data were correlated with HER2 IHC results.</p><p><strong>Results: </strong>166 patients with thoracic tumour samples had HER2 expression assessed: 46% were IHC 0, 28% IHC 1+, 13% IHC 2+ and 13% IHC 3+. HER2 IHC scores were overall lower for cytology cell blocks as compared with surgical pathology specimens; 79% of cases with paired specimens had a decrease in their HER2 IHC score from their surgical specimen to their paired cytology specimen. Of specimens with HER2 IHC 3+ and NGS available, only 14% (3/21) had concomitant ERBB2 alterations. Among all specimens, ERBB2 point mutations were noted in 4% (4/110) and ERBB2 amplification in 3% (3/110). The majority of HER2 3+ cases with paired NGS (17/21, 81%) had non-<i>ERBB2</i> genomic alterations, including: <i>KRAS</i>, <i>TP53,</i> and <i>STK11</i> mutations.</p><p><strong>Conclusions: </strong>HER2 IHC 3+ is seen in a small but clinically significant proportion of samples and is associated with a variety of co-occurring non-ERBB2 genomic alterations. Preanalytical variables including specimen fixation can significantly impact the assessment of HER2 expression via immunohistochemistry.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"24-30"},"PeriodicalIF":2.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12216975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and outcomes of myeloid neoplasms with MECOM rearrangements. 髓系肿瘤伴MECOM重排的临床特点及预后。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-12-13 DOI: 10.1136/jcp-2025-210232
Chantana Polprasert, Chinadol Wanitpongpun, Chantiya Chanswangphuwana, Thanawat Rattanathammethee, Pimjai Niparuck, Narittee Suksawai, Ponthip Mekchay, Weerapat Owattanapanich, Smith Kungwankiattichai, Ekarat Rattarittamrong, Adisak Tantiworawit, Wasithep Limvorapitak, Supawee Saengboon, Jakrawadee Julamanee, Pirun Saelue, Kannadit Prayongratana, Ekapun Karoopongse, Ponlapat Rojnuckarin, Suporn Chuncharunee, Chantrapa Sriswasdi
{"title":"Clinical characteristics and outcomes of myeloid neoplasms with <i>MECOM</i> rearrangements.","authors":"Chantana Polprasert, Chinadol Wanitpongpun, Chantiya Chanswangphuwana, Thanawat Rattanathammethee, Pimjai Niparuck, Narittee Suksawai, Ponthip Mekchay, Weerapat Owattanapanich, Smith Kungwankiattichai, Ekarat Rattarittamrong, Adisak Tantiworawit, Wasithep Limvorapitak, Supawee Saengboon, Jakrawadee Julamanee, Pirun Saelue, Kannadit Prayongratana, Ekapun Karoopongse, Ponlapat Rojnuckarin, Suporn Chuncharunee, Chantrapa Sriswasdi","doi":"10.1136/jcp-2025-210232","DOIUrl":"https://doi.org/10.1136/jcp-2025-210232","url":null,"abstract":"","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating tumour heterogeneity in a melanoma arising in congenital melanocytic nevus using in situ spatial gene expression analysis. 利用原位空间基因表达分析研究先天性黑素细胞痣中黑色素瘤的肿瘤异质性。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-12-09 DOI: 10.1136/jcp-2025-210509
Jutapak Jenkitkonchai, Kittiporn Punuch, Teerapat Paringkarn, Teerapat Wannawittayapa, Manop Pithukpakorn, Panitta Sitthinamsuwan, Manasmon Chairatchaneeboon, Varodom Charoensawan
{"title":"Investigating tumour heterogeneity in a melanoma arising in congenital melanocytic nevus using in situ spatial gene expression analysis.","authors":"Jutapak Jenkitkonchai, Kittiporn Punuch, Teerapat Paringkarn, Teerapat Wannawittayapa, Manop Pithukpakorn, Panitta Sitthinamsuwan, Manasmon Chairatchaneeboon, Varodom Charoensawan","doi":"10.1136/jcp-2025-210509","DOIUrl":"https://doi.org/10.1136/jcp-2025-210509","url":null,"abstract":"","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Appraisal of hydatidiform mole incidence and registration rates in Ireland following the establishment of a National Gestational Trophoblastic Disease Registry. 评估爱尔兰妊娠滋养细胞疾病国家登记处成立后的水滴形痣发病率和登记率。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-11-19 DOI: 10.1136/jcp-2023-209270
Caroline M Joyce, Craig Wakefield, Daphne Chen-Maxwell, Susan Dineen, Caitriona Kenneally, Paul Downey, Catherine Duffy, Keelin O'Donoghue, John Coulter, Brendan Fitzgerald

Aims: This study aimed to re-evaluate the incidence of hydatidiform mole (HM) and determine gestational trophoblastic disease (GTD) registration rates in Ireland following the establishment of the National GTD Registry in 2017.

Methods: We performed a 3-year retrospective audit of HM cases (January 2017 to December 2019) reported in our centre. In 2019, we surveyed Irish pathology laboratories to determine the number of HMs diagnosed nationally and compared this data to that recorded in the National GTD Registry. Additionally, we compared both local and national HM incidence rates to those reported internationally.

Results: In the 3-year local audit, we identified 87 HMs among 1856 products of conception (POCs) providing a local HM incidence rate of 3.92 per 1000 births. The 1-year pathology survey recorded 170 HMs in 6008 POCs, yielding a national incidence rate of 2.86 per 1000 births. Importantly, the local HM incidence rate exceeded the national incidence rate by 37% and the local partial HM incidence (1 in 296 births) was 64% higher than the nationally incidence rate (1 in 484 births). Notably, 42% of the HM and atypical POCs diagnosed nationally were not reported to the National GTD Registry.

Conclusions: Our study reveals increased HM incidence rates both locally and nationally compared with previous Irish studies. The higher local PHM incidence may reflect more limited access to ploidy analysis in other pathology laboratories nationally. Significantly, almost half of the women with diagnosed or suspected HM were not registered with the National GTD Centre.

目的:本研究旨在重新评估水滴形痣(HM)的发病率,并确定2017年国家GTD登记处成立后爱尔兰的妊娠滋养细胞疾病(GTD)登记率:我们对本中心报告的HM病例(2017年1月至2019年12月)进行了为期3年的回顾性审计。2019年,我们对爱尔兰病理实验室进行了调查,以确定全国确诊的HM数量,并将该数据与国家GTD登记处记录的数据进行了比较。此外,我们还将本地和全国的HM发病率与国际报告的发病率进行了比较:在为期 3 年的地方审核中,我们在 1856 例受孕产品 (POC) 中发现了 87 例 HM,地方 HM 发病率为每 1000 例新生儿 3.92 例。为期 1 年的病理调查记录了 6008 个受孕产品中的 170 例 HM,全国发病率为每 1000 名新生儿 2.86 例。重要的是,地方 HM 发病率比全国发病率高出 37%,地方部分 HM 发病率(每 296 例新生儿中 1 例)比全国发病率(每 484 例新生儿中 1 例)高出 64%。值得注意的是,在全国确诊的 HM 和非典型 POC 中,有 42% 没有向全国 GTD 登记处报告:我们的研究表明,与之前的爱尔兰研究相比,当地和全国的 HM 发病率都有所上升。当地 PHM 发生率较高可能反映出全国其他病理实验室进行倍性分析的机会较为有限。值得注意的是,近一半确诊或疑似 HM 的妇女没有在国家 GTD 中心登记。
{"title":"Appraisal of hydatidiform mole incidence and registration rates in Ireland following the establishment of a National Gestational Trophoblastic Disease Registry.","authors":"Caroline M Joyce, Craig Wakefield, Daphne Chen-Maxwell, Susan Dineen, Caitriona Kenneally, Paul Downey, Catherine Duffy, Keelin O'Donoghue, John Coulter, Brendan Fitzgerald","doi":"10.1136/jcp-2023-209270","DOIUrl":"10.1136/jcp-2023-209270","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to re-evaluate the incidence of hydatidiform mole (HM) and determine gestational trophoblastic disease (GTD) registration rates in Ireland following the establishment of the National GTD Registry in 2017.</p><p><strong>Methods: </strong>We performed a 3-year retrospective audit of HM cases (January 2017 to December 2019) reported in our centre. In 2019, we surveyed Irish pathology laboratories to determine the number of HMs diagnosed nationally and compared this data to that recorded in the National GTD Registry. Additionally, we compared both local and national HM incidence rates to those reported internationally.</p><p><strong>Results: </strong>In the 3-year local audit, we identified 87 HMs among 1856 products of conception (POCs) providing a local HM incidence rate of 3.92 per 1000 births. The 1-year pathology survey recorded 170 HMs in 6008 POCs, yielding a national incidence rate of 2.86 per 1000 births. Importantly, the local HM incidence rate exceeded the national incidence rate by 37% and the local partial HM incidence (1 in 296 births) was 64% higher than the nationally incidence rate (1 in 484 births). Notably, 42% of the HM and atypical POCs diagnosed nationally were not reported to the National GTD Registry.</p><p><strong>Conclusions: </strong>Our study reveals increased HM incidence rates both locally and nationally compared with previous Irish studies. The higher local PHM incidence may reflect more limited access to ploidy analysis in other pathology laboratories nationally. Significantly, almost half of the women with diagnosed or suspected HM were not registered with the National GTD Centre.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"822-829"},"PeriodicalIF":2.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12703346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140329834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sinonasal alveolar rhabdomyosarcoma with PAX3::NCOA1 fusion expressing SOX10 and with nodal metastases: a double diagnostic pitfall. 鼻窦肺泡横纹肌肉瘤伴有表达 SOX10 的 PAX3::NCOA1 融合和结节转移:双重诊断陷阱。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-11-19 DOI: 10.1136/jcp-2024-209640
Hannah Crane, Robin J Young, Malee S Fernando, Jon Griffin
{"title":"Sinonasal alveolar rhabdomyosarcoma with <i>PAX3::NCOA1</i> fusion expressing SOX10 and with nodal metastases: a double diagnostic pitfall.","authors":"Hannah Crane, Robin J Young, Malee S Fernando, Jon Griffin","doi":"10.1136/jcp-2024-209640","DOIUrl":"10.1136/jcp-2024-209640","url":null,"abstract":"","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"864-866"},"PeriodicalIF":2.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating somatic variants and pathways in mismatch repair-deficient (dMMR) colorectal carcinoma in South Africa. 调查南非错配修复缺陷(dMMR)结直肠癌的体细胞变异和途径。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-11-19 DOI: 10.1136/jcp-2024-209526
Alessandro Pietro Aldera, Jana van der Westhuizen, Wan-Jung Tsai, May J Krause, Safiye Yildiz, Komala Pillay, Adam Boutall, Raj Ramesar

Aims: Colorectal carcinoma (CRC) is a common cause of morbidity and mortality worldwide, and an emerging public health problem in sub-Saharan Africa. Several authors have described an increased frequency of mismatch repair-deficient (dMMR) CRC in sub-Saharan Africa, but these tumours remain poorly characterised molecularly. We sought to interrogate the somatic molecular genetic landscape of dMMR CRC in a cohort of young patients to better inform Lynch syndrome (LS) screening strategies and personalised medicine approaches in our setting.

Methods: 32 patients (aged <60 years) were identified with dMMR CRC. DNA was extracted from selected formalin-fixed paraffin-embedded (FFPE) tissue resection samples and subjected to amplicon-based next-generation sequencing (NGS).

Results: Pathogenic or likely pathogenic variants were detected in the corresponding MMR gene in 14 of 18 (78%) MLH1/PMS2-deficient tumours, 5 of 8 (63%) MSH2/MSH6-deficient tumours, 1 of 4 (25%) tumours with isolated MSH6 loss and 0 of 2 tumours with isolated PMS2 loss. Previously unreported variants were identified in MLH1 (three) and MSH2 (one). Cases with a variant allele frequency suggesting a germline mutation were identified in MLH1 (eight), MSH2 (two) and MSH6 (one). Only one MMR gene variant was detected in more than one patient (MLH1 p.Q510*). Four POLE/POLD1 exonuclease domain variants were identified, one of which was previously unreported.

Conclusion: The spectrum of disease-causing MMR gene variants in our population necessitates NGS testing for LS screening. This study also highlights the role of somatic testing on readily available FFPE samples to generate data on the epidemiology of CRC in different settings.

目的:结直肠癌(CRC)是全球常见的发病和死亡原因,也是撒哈拉以南非洲地区新出现的公共卫生问题。一些学者描述了撒哈拉以南非洲地区错配修复缺陷型(dMMR)结直肠癌发病率增加的情况,但这些肿瘤的分子特征仍然很不清楚。我们试图在一组年轻患者中调查 dMMR CRC 的体细胞分子遗传学情况,以便更好地为我们的林奇综合征(LS)筛查策略和个性化医疗方法提供信息:18例MLH1/PMS2缺失肿瘤中的14例(78%)、8例MSH2/MSH6缺失肿瘤中的5例(63%)、4例孤立MSH6缺失肿瘤中的1例(25%)以及2例孤立PMS2缺失肿瘤中的0例,均在相应的MMR基因中检测到致病或可能致病的变异。在 MLH1(3 例)和 MSH2(1 例)中发现了以前未报道过的变异。在 MLH1(8 例)、MSH2(2 例)和 MSH6(1 例)中发现了变异等位基因频率表明存在种系突变的病例。只有一个 MMR 基因变异在不止一名患者中被检测到(MLH1 p.Q510*)。发现了4个POLE/POLD1外切酶结构域变异,其中一个变异此前未被报道:结论:我国人群中致病的 MMR 基因变异的范围很广,因此有必要在 LS 筛查中进行 NGS 测试。本研究还强调了在现成的 FFPE 样本上进行体细胞检测的作用,以获得不同环境下 CRC 流行病学的数据。
{"title":"Investigating somatic variants and pathways in mismatch repair-deficient (dMMR) colorectal carcinoma in South Africa.","authors":"Alessandro Pietro Aldera, Jana van der Westhuizen, Wan-Jung Tsai, May J Krause, Safiye Yildiz, Komala Pillay, Adam Boutall, Raj Ramesar","doi":"10.1136/jcp-2024-209526","DOIUrl":"10.1136/jcp-2024-209526","url":null,"abstract":"<p><strong>Aims: </strong>Colorectal carcinoma (CRC) is a common cause of morbidity and mortality worldwide, and an emerging public health problem in sub-Saharan Africa. Several authors have described an increased frequency of mismatch repair-deficient (dMMR) CRC in sub-Saharan Africa, but these tumours remain poorly characterised molecularly. We sought to interrogate the somatic molecular genetic landscape of dMMR CRC in a cohort of young patients to better inform Lynch syndrome (LS) screening strategies and personalised medicine approaches in our setting.</p><p><strong>Methods: </strong>32 patients (aged <60 years) were identified with dMMR CRC. DNA was extracted from selected formalin-fixed paraffin-embedded (FFPE) tissue resection samples and subjected to amplicon-based next-generation sequencing (NGS).</p><p><strong>Results: </strong>Pathogenic or likely pathogenic variants were detected in the corresponding MMR gene in 14 of 18 (78%) MLH1/PMS2-deficient tumours, 5 of 8 (63%) MSH2/MSH6-deficient tumours, 1 of 4 (25%) tumours with isolated MSH6 loss and 0 of 2 tumours with isolated PMS2 loss. Previously unreported variants were identified in <i>MLH1</i> (three) and <i>MSH2</i> (one). Cases with a variant allele frequency suggesting a germline mutation were identified in <i>MLH1</i> (eight), <i>MSH2</i> (two) and <i>MSH6</i> (one). Only one MMR gene variant was detected in more than one patient (<i>MLH1</i> p.Q510*). Four <i>POLE/POLD1</i> exonuclease domain variants were identified, one of which was previously unreported.</p><p><strong>Conclusion: </strong>The spectrum of disease-causing MMR gene variants in our population necessitates NGS testing for LS screening. This study also highlights the role of somatic testing on readily available FFPE samples to generate data on the epidemiology of CRC in different settings.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"848-854"},"PeriodicalIF":2.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140945042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts. 不同部位腺癌中 Claudin18.2 的表达及其临床病理特征
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-11-19 DOI: 10.1136/jcp-2023-209268
Pingping Yan, Yu Dong, Fenfen Zhang, Tiantian Zhen, Jiangtao Liang, Huijuan Shi, Anjia Han

Aims: To clarify claudin18.2 expression and its clinicopathological features in various cancers, especially in lung adenocarcinoma.

Methods: Immunohistochemistry staining and fluorescence in situ hybridisation (FISH) were performed to detect claudin18.2 expression and CLDN18 gene rearrangement in adenocarcinoma from different organs.

Results: The results showed that claudin18.2 expression was found in 68% (27 of 40) of lung mucinous adenocarcinoma, 52% (16 of 31) of cholangiocarcinoma, 2% (10 of 423) of colorectal adenocarcinoma tissue microarray, 27% (6 of 22) of colorectal mucinous adenocarcinoma and 30% (3 of 10) of cervical adenocarcinoma, but not in all 39 cases of invasive breast adenocarcinoma by immunohistochemistry staining. There was significantly positive correlation between ratio of claudin18.2-positive carcinoma cells and staining intensity in lung mucinous adenocarcinoma and cholangiocarcinoma. Claudin18.2 expression was much more in female patients than male patients with lung mucinous adenocarcinoma. In addition, cholangiocarcinoma with claudin18.2 expression was more aggressive and had perineural invasion. Intraductal papillary neoplasm of the bile duct and epithelial dysplasia of the adjacent bile in cholangiocarcinoma also showed claudin18.2 expression. All three cases of cervical adenocarcinoma with claudin18.2 expression were moderately differentiated adenocarcinoma including one human papillomavirus (HPV)-associated carcinoma, two non-HPV-associated and gastric-type carcinoma. CLDN18 gene rearrangement was not found in all 22 cases with high claudin18.2 expression by FISH.

Conclusions: Our results suggest claudin18.2 might be a potential biomarker for targeted therapy on lung mucinous adenocarcinoma, cholangiocarcinoma, colorectal mucinous adenocarcinoma and gastric-type cervical adenocarcinoma.

目的:阐明claudin18.2在各种癌症,尤其是肺腺癌中的表达及其临床病理特征:免疫组化染色和荧光原位杂交(FISH)检测不同器官腺癌中 claudin18.2 的表达和 CLDN18 基因重排情况:结果:结果显示,68%的腺癌中发现了claudin18.2在68%的肺黏液腺癌(40例中的27例)、52%的胆管癌(31例中的16例)、2%的结直肠腺癌(423例中的10例)组织芯片中均有表达、27%(22 例中的 6 例)的结直肠黏液腺癌和 30%(10 例中的 3 例)的宫颈腺癌,但在所有 39 例浸润性乳腺腺癌中,免疫组化染色结果均未显示出这一结果。在肺粘液腺癌和胆管癌中,Claudin18.2阳性癌细胞的比例与染色强度呈明显的正相关。女性肺粘液腺癌患者的 Claudin18.2 表达远高于男性。此外,有 Claudin18.2 表达的胆管癌更具侵袭性,并有神经周围浸润。胆管癌中的胆管导管内乳头状肿瘤和邻近胆汁的上皮发育不良也有claudin18.2表达。3例有claudin18.2表达的宫颈腺癌均为中度分化腺癌,包括1例人乳头瘤病毒(HPV)相关癌、2例非HPV相关癌和胃型癌。通过 FISH 检测,在所有 22 例高 claudin18.2 表达的病例中均未发现 CLDN18 基因重排:我们的研究结果表明,claudin18.2可能是肺粘液腺癌、胆管癌、结直肠粘液腺癌和胃型宫颈腺癌靶向治疗的潜在生物标志物。
{"title":"Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts.","authors":"Pingping Yan, Yu Dong, Fenfen Zhang, Tiantian Zhen, Jiangtao Liang, Huijuan Shi, Anjia Han","doi":"10.1136/jcp-2023-209268","DOIUrl":"10.1136/jcp-2023-209268","url":null,"abstract":"<p><strong>Aims: </strong>To clarify claudin18.2 expression and its clinicopathological features in various cancers, especially in lung adenocarcinoma.</p><p><strong>Methods: </strong>Immunohistochemistry staining and fluorescence in situ hybridisation (FISH) were performed to detect claudin18.2 expression and <i>CLDN18</i> gene rearrangement in adenocarcinoma from different organs.</p><p><strong>Results: </strong>The results showed that claudin18.2 expression was found in 68% (27 of 40) of lung mucinous adenocarcinoma, 52% (16 of 31) of cholangiocarcinoma, 2% (10 of 423) of colorectal adenocarcinoma tissue microarray, 27% (6 of 22) of colorectal mucinous adenocarcinoma and 30% (3 of 10) of cervical adenocarcinoma, but not in all 39 cases of invasive breast adenocarcinoma by immunohistochemistry staining. There was significantly positive correlation between ratio of claudin18.2-positive carcinoma cells and staining intensity in lung mucinous adenocarcinoma and cholangiocarcinoma. Claudin18.2 expression was much more in female patients than male patients with lung mucinous adenocarcinoma. In addition, cholangiocarcinoma with claudin18.2 expression was more aggressive and had perineural invasion. Intraductal papillary neoplasm of the bile duct and epithelial dysplasia of the adjacent bile in cholangiocarcinoma also showed claudin18.2 expression. All three cases of cervical adenocarcinoma with claudin18.2 expression were moderately differentiated adenocarcinoma including one human papillomavirus (HPV)-associated carcinoma, two non-HPV-associated and gastric-type carcinoma. <i>CLDN18</i> gene rearrangement was not found in all 22 cases with high claudin18.2 expression by FISH.</p><p><strong>Conclusions: </strong>Our results suggest claudin18.2 might be a potential biomarker for targeted therapy on lung mucinous adenocarcinoma, cholangiocarcinoma, colorectal mucinous adenocarcinoma and gastric-type cervical adenocarcinoma.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"815-821"},"PeriodicalIF":2.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12703292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Joint online distance learning to complement postgraduate pathology training in preparation for national board examinations. 联合在线远程学习,补充研究生病理学培训,为国家委员会考试做准备。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-11-19 DOI: 10.1136/jcp-2023-209311
Bas de Leng, Laura Helle, Otto Jokelainen, Mikko Kainulainen, Pauliina Kronqvist, Christian Mol, Friedrich Pawelka, Vesa-Matti Pohjanen, Koen Vincken

Aims: To meet the flexible learning needs of pathology residents preparing for national board examinations, a joint distance learning approach was developed using both asynchronous and synchronous activities with whole slide images, drawing on empirical educational research on online distance learning.

Methods: In a case study of an implementation of the designed joint distance learning approach with a geographically dispersed group of pathology residents in Finland, the participants' perceptions were measured with a 12-item questionnaire covering the value of the learning opportunity, the quality of the sociocognitive processes and their emotional engagement and social cohesion. Communication during the online session was also recorded and analysed to provide objectivity to the self-report data.

Results: The effectiveness of joint online learning for knowledge acquisition and preparation for national board examinations was highly rated. However, despite strong emotional engagement during synchronous activities, participants reported minimal interpersonal interaction, which was also reflected in the recordings of the online session.

Conclusion: Using a technology integration framework and guided by the principles of self-determination theory, joint distance learning is emerging as a beneficial addition to postgraduate pathology programmes in preparation for national examinations. However, to realise the full potential of interpersonal interaction, participants should be prepared for an appropriate mindset.

目的:为了满足准备参加国家医师资格考试的病理学住院医师的灵活学习需求,我们借鉴在线远程学习的经验性教育研究,开发了一种利用整张幻灯片图像进行异步和同步活动的联合远程学习方法:在对芬兰病理学住院医师群体实施所设计的联合远程学习方法的案例研究中,通过一份包含 12 个项目的调查问卷测量了参与者的看法,其中包括学习机会的价值、社会认知过程的质量以及他们的情感投入和社会凝聚力。此外,还对在线课程期间的交流进行了记录和分析,以确保自我报告数据的客观性:结果:联合在线学习在获取知识和准备国家考试方面的有效性得到了高度评价。然而,尽管在同步活动中参与者的情感参与度很高,但他们报告的人际互动却很少,在线课程的录音也反映了这一点:利用技术整合框架,在自我决定理论原则的指导下,联合远程学习正在成为病理学研究生课程的有益补充,为国家考试做准备。然而,为了充分发挥人际互动的潜力,参与者应做好适当的思想准备。
{"title":"Joint online distance learning to complement postgraduate pathology training in preparation for national board examinations.","authors":"Bas de Leng, Laura Helle, Otto Jokelainen, Mikko Kainulainen, Pauliina Kronqvist, Christian Mol, Friedrich Pawelka, Vesa-Matti Pohjanen, Koen Vincken","doi":"10.1136/jcp-2023-209311","DOIUrl":"10.1136/jcp-2023-209311","url":null,"abstract":"<p><strong>Aims: </strong>To meet the flexible learning needs of pathology residents preparing for national board examinations, a joint distance learning approach was developed using both asynchronous and synchronous activities with whole slide images, drawing on empirical educational research on online distance learning.</p><p><strong>Methods: </strong>In a case study of an implementation of the designed joint distance learning approach with a geographically dispersed group of pathology residents in Finland, the participants' perceptions were measured with a 12-item questionnaire covering the value of the learning opportunity, the quality of the sociocognitive processes and their emotional engagement and social cohesion. Communication during the online session was also recorded and analysed to provide objectivity to the self-report data.</p><p><strong>Results: </strong>The effectiveness of joint online learning for knowledge acquisition and preparation for national board examinations was highly rated. However, despite strong emotional engagement during synchronous activities, participants reported minimal interpersonal interaction, which was also reflected in the recordings of the online session.</p><p><strong>Conclusion: </strong>Using a technology integration framework and guided by the principles of self-determination theory, joint distance learning is emerging as a beneficial addition to postgraduate pathology programmes in preparation for national examinations. However, to realise the full potential of interpersonal interaction, participants should be prepared for an appropriate mindset.</p>","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"843-847"},"PeriodicalIF":2.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12703318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Authors' reply: megablocks are nice but not really necessary. 作者回复:megablocks 固然不错,但并无必要。
IF 2 4区 医学 Q2 PATHOLOGY Pub Date : 2025-11-19 DOI: 10.1136/jcp-2024-209665
Murali Varma, John Dormer
{"title":"Authors' reply: megablocks are nice but not really necessary.","authors":"Murali Varma, John Dormer","doi":"10.1136/jcp-2024-209665","DOIUrl":"10.1136/jcp-2024-209665","url":null,"abstract":"","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"863"},"PeriodicalIF":2.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1